---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014654"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:55:49.445798+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off

## Summary
- Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).
- Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.
- Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.
- Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.
- Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%.

## SEC filing metadata
- accession: 0001493152-26-014654
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014654
- JSON: https://secwatch.observer/filing/0001493152-26-014654.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014654.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported fourth quarter and fiscal year ended December 31, 2025 results: revenue $9.2 million and $38.7 million, respectively, net income $22.8 million and $25.0 million, respectively.
  - Period: fourth quarter and fiscal year ended December 31, 2025
  - Revenue: $9.2 million and $38.7 million, respectively
  - Net income: $22.8 million and $25.0 million, respectively
  - Result: reported results
  source text: stated in such filing. --- EX-99.1 (EX-99.1) --- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results ● Q4 and FY Revenue of $9.2 million and $38.7 million ● Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.